Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-Specific CAR T Cells + JSMD194 in Relapsed/Persistent Multiple Myeloma
NCT03502577Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenigacestat in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Maximum tolerated dose of chimeric antigen receptor (CAR) T cells at 28 days and Incidence of general toxicities at 1 year. Started May 2018; status: terminated.
02
Drugs
crenigacestat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03502577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502577.